1619 – Testing of blood to detect pathogenic germline BRCA1 or BRCA2 gene variants, in patients with metastatic pancreatic cancer to help determine eligibility for PBS olaparib

Page last updated: 21 September 2020

Application Detail

Description of Medical Service

Testing of blood for germline BRCA 1/2 mutations in patients with metastatic pancreatic cancer. The purpose of the test is to determine eligibility for PBS olaparib (i.e. treatment of patients whose disease does not progress following first line treatment with platinum based chemotherapy).

Description of Medical Condition

Pancreatic cancer has one of the lowest 5 year survival rates with a 9.8% survival rate for the period 2011-2015. The prognosis of this cancer has not improved significantly over the past 20 years, and the incidence and mortality rates are very similar. A total of 3307 cases of pancreatic cancer were reported in 2015, with 2911 deaths due to pancreatic cancer in 2016. It is estimated that pancreatic cancer will be the fourth most common cause of death due to cancer in 2019. The poor prognosis for pancreatic cancer is directly related to late diagnosis, when the disease is often locally advanced or metastatic, and surgery is not an option. Carriers of germline mutations in BRCA1/2 genes are known to have an increased risk of pancreatic cancer with up to 7% of unselected pancreatic cancer cases having a germline BRCA 1/2 mutation.

Reason for Application

New MBS item

Medical Service Type


Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1620 KB)
Application Form (Word 253 KB)

Consultation Survey

Consultation Survey (PDF 561 KB)
Consultation Survey (Word 70 KB)

PICO Confirmation

PICO Confirmation (PDF 1769 KB)
PICO Confirmation (Word 566 KB)

Assessment Report


Public Summary Document


Meetings for this Application


16-17 April 2020